Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors

BACKGROUND: M4112 is an oral, potent, and selective indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2) dual inhibitor. Here, we report preclinical data and first-in-human phase I data, including safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, Aung, Eder, Joseph P, Piha-Paul, Sarina A, Gimmi, Claude, Hussey, Elizabeth, Zhang, Sen, Hildebrand, Vera, Hosagrahara, Vinayak, Habermehl, Christina, Moisan, Jacques, Papadopoulos, Kyriakos P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449315/
https://www.ncbi.nlm.nih.gov/pubmed/32843490
http://dx.doi.org/10.1136/jitc-2020-000870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449315/
https://www.ncbi.nlm.nih.gov/pubmed/32843490
http://dx.doi.org/10.1136/jitc-2020-000870

Ejemplares similares